chr4-1938448-TAGAG-T
Position:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_001042424.3(NSD2):c.1676_1679del(p.Arg559ThrfsTer38) variant causes a splice acceptor, coding sequence change. The variant allele was found at a frequency of 0.00000224 in 894,778 control chromosomes in the GnomAD database, with no homozygous occurrence. 1/1 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: not found (cov: 18)
Exomes 𝑓: 0.0000022 ( 0 hom. )
Consequence
NSD2
NM_001042424.3 splice_acceptor, coding_sequence
NM_001042424.3 splice_acceptor, coding_sequence
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 5.97
Genes affected
NSD2 (HGNC:12766): (nuclear receptor binding SET domain protein 2) This gene encodes a protein that contains four domains present in other developmental proteins: a PWWP domain, an HMG box, a SET domain, and a PHD-type zinc finger. It is expressed ubiquitously in early development. Wolf-Hirschhorn syndrome (WHS) is a malformation syndrome associated with a hemizygous deletion of the distal short arm of chromosome 4. This gene maps to the 165 kb WHS critical region and has also been involved in the chromosomal translocation t(4;14)(p16.3;q32.3) in multiple myelomas. Alternative splicing of this gene results in multiple transcript variants encoding different isoforms. Some transcript variants are nonsense-mediated mRNA (NMD) decay candidates, hence not represented as reference sequences. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PVS1
Splicing +-2 bp (donor or acceptor) variant, product NOT destroyed by NMD, known LOF gene, truncates exone, which is 0.01976574 fraction of the gene. Cryptic splice site detected, with MaxEntScore 5.8, offset of 0 (no position change), new splice context is: tttttttttttaaataatAGaca. Cryptic site results in inframe change. If cryptic site found is not functional and variant results in exon loss, it results in frameshift change.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 4-1938448-TAGAG-T is Pathogenic according to our data. Variant chr4-1938448-TAGAG-T is described in ClinVar as [Pathogenic]. Clinvar id is 547999.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr4-1938448-TAGAG-T is described in Lovd as [Pathogenic]. Variant chr4-1938448-TAGAG-T is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NSD2 | NM_001042424.3 | c.1676_1679del | p.Arg559ThrfsTer38 | splice_acceptor_variant, coding_sequence_variant | 8/22 | ENST00000508803.6 | NP_001035889.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NSD2 | ENST00000508803.6 | c.1676_1679del | p.Arg559ThrfsTer38 | splice_acceptor_variant, coding_sequence_variant | 8/22 | 1 | NM_001042424.3 | ENSP00000423972 | P1 |
Frequencies
GnomAD3 genomes Cov.: 18
GnomAD3 genomes
Cov.:
18
GnomAD4 exome AF: 0.00000224 AC: 2AN: 894778Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 463916
GnomAD4 exome
AF:
AC:
2
AN:
894778
Hom.:
AF XY:
AC XY:
0
AN XY:
463916
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 18
GnomAD4 genome
Cov.:
18
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:10
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Rauch-Steindl syndrome Pathogenic:3
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 11, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center | Mar 17, 2022 | PVS2, PS2, PM2 - |
Pathogenic, criteria provided, single submitter | clinical testing | New York Genome Center | Oct 26, 2022 | The de novo c.1676_1679del variant identified in the NSD2 gene has previously been reported as de novo variant in individuals with NSD2-related disorder with features of developmental delay, cardiac defects, and multiple congenital malformations [PMID: 30345613, 26785492, 33144682] and it has been deposited in ClinVar [ClinVar ID: 547999] as Pathogenic. The c.1676_1679del variant is observed in 1 allele (~0.00062% minor allele frequency with 0 homozygotes) in population databases (gnomAD v2.1.1 and v3.1.2, TOPMed Freeze 8, All of Us), suggesting it is not a common benign variant in the populations represented in those databases. The c.1676_1679del variant in NSD2 is located in exon 8 of this 22-exon gene, predicted to incorporate a premature termination codon approximately 38 amino acids downstream (p.(Arg559ThrfsTer38)), and is expected to result in loss-of-function via nonsense mediated decay. Multiple loss-of-function variants that are downstream to the c.1676_1679del variant have been reported in the literature [PMID: 31382906, 33941880] and ClinVar [ClinVar ID: 1333177] in individuals with Rauch-Steindl syndrome. Based on available evidence this de novo c.1676_1679del (p.(Arg559ThrfsTer38)), variant identified in NSD2 is classified here as Pathogenic. - |
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 08, 2023 | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 33144682, 30345613, 26785492, 32368696, 33084842) - |
Pathogenic, no assertion criteria provided | clinical testing | Molecular Genetics laboratory, Necker Hospital | Sep 07, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Feb 01, 2020 | - - |
NSD2-related disorder Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Aug 14, 2024 | The NSD2 c.1676_1679delGAGA variant is predicted to result in a frameshift and premature protein termination (p.Arg559Thrfs*38). This variant was reported de novo in at least one individual with congenital heart disease (as 4:1940175 TAGAG>T in WHSC1; Dataset S2, Homsy et al. 2015. PubMed ID: 26785492; Dataset S2, Sevim Bayrak et al. 2020. PubMed ID: 31941532; Edwards et al. 2020. PubMed ID: 32368696; eTable 4, Morton et al. 2021. PubMed ID: 33084842) and also was reported de novo in at least one individual with developmental delays, mild facial dysmorphisms, short stature, failure to thrive, and microcephaly (as: c.1676_1679del (p.Arg559Tfs*38) in WHSC1; Boczek et al. 2018. PubMed ID: 30345613; Klee et al. 2020. PubMed ID: 33144682). This variant has not been reported in a large population database, indicating this variant is rare. Frameshift variants in NSD2 are expected to be pathogenic. This variant is interpreted as likely pathogenic. - |
Global developmental delay Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | 3billion | Oct 25, 2021 | Frameshift: predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple pathogenic variants are reported downstream of the variant (PVS1). It is not observed in the gnomAD v2.1.1 dataset (PM2). The variant has been reported to be associated with [GeneName] related disorder (ClinVar ID: VCV000547999.8). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. - |
Neurodevelopmental delay Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Centre de Biologie Pathologie Génétique, Centre Hospitalier Universitaire de Lille | - | - - |
4p partial monosomy syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Sep 29, 2017 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_AG_spliceai
Position offset: 7
DS_AL_spliceai
Position offset: 3
Find out detailed SpliceAI scores and Pangolin per-transcript scores at